In this edition of Cardio Conversations, Medtech Insight talked to Théophile Mohr Durdez, the CEO and co-founder of Volta Medical, a Marseille based company applying artificial intelligence to electrophysiology. Volta has raised over €70m and is sponsoring TAILORED-AF to evaluate its atrial fibrillation ablation guided by its VXI decision-support software.


More on AI and electrophysiology from Medtech Insight:

https://medtech.pharmaintelligence.informa.com/MT147825/Cardio-Conversations-Vektor-Addresses-Global-Health-Crisis-With-Arrythmia-Mapping

https://medtech.pharmaintelligence.informa.com/MT147560/Cardio-Conversations-Steven-Mickelsen-Discusses-PFA-Electrophysiology-And-What-It-Takes-To-Be-A-Physician-Inventor

https://medtech.pharmaintelligence.informa.com/MT145760/Cardio-CatchUp-Arga-HeartPoint-Plan-FirstInHuman-Trials-Of-Novel-Devices-Medtronic-And-Edwards-Announce-Product-Launches-And-More

https://medtech.pharmaintelligence.informa.com/MT145539/Cardio-CatchUp-Updates-From-BSecur-egnite-Vektor-And-Other-UnderTheRadar-Companies

https://medtech.pharmaintelligence.informa.com/MT122844/New-AI-Tech-To-Improve-AFib-Treatment-Slated-For-2020-Market-Launch

Cardio Conversations: Volta Has Big Ambitions For AI In EP

Audio roundup of selected biopharma industry content from Scrip over the business week ended 25 October 2024. In this episode: Merck & Co’s Modifi acquisition; scenarios for new obesity drugs; Astellas gets US approval for claudin drug Vyloy; iTeos builds TIGIT lead; and execs discuss AI in clinical trials.
https://insights.citeline.com/scrip/quick-listen-scrips-five-must-know-things-YMAHSAK2FBBKPIPNLZGPGHWPSQ/

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Scrip's Five Must-Know Things - 28 October 2024

Health technologies are revolutionizing the ways in which life sciences organizations develop and deliver life-saving treatments to patients. In particular, digital therapeutics have become a prominent area of focus due to their potential to improve outcomes while reducing patient burden. Norstella continues to be proponent for these innovative technologies, partnering with organizations to launch their digital therapeutics products to market both seamlessly and with the patient in mind. That being said, we always stay up to date with the evolving landscape by attending meetings that bring together decision-makers with diverse expertise and fresh perspectives.

LSX World Congress USA, which took place between September 11-12, 2024 in Boston, MA, addressed the complex investment, partnership, and innovation aspects of digital therapeutics. After attending the conference, Janelle Hart, managing editor, custom content at Citeline, sat down with principal and head of Digital Health & Access Innovation Strategy Tony Shi and consultant Eric Boyda from The Dedham Group, a Norstella company, to explore key takeaways from the meeting, what the future holds for digital therapeutics, and how Norstella and the Dedham Group are making strides in this sector to smooth the path from pipeline to patient.

To listen to part 1 of this podcast, go to this link: https://soundcloud.com/citelinesounds/lsx-world-congress-usa-key-takeaways?si=6fa75aae9d7f45febcfe0bb6762a62aa&utm_source=clipboard&utm_medium=text&utm_campaign=social_sharing

For more information on Norstella’s capabilities as a healthcare technology partner, visit: https://www.norstella.com/

To learn more about the Dedham Group, contact Tony or Eric at: tony.shi@norstella.com or eric.boyda@norstella.com 


Conference Catch-Up: The Rise of Digital Therapeutics (Part 2)

世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。
今回取り上げた記事はこちら
「Déjà Vu In England: Lilly’s Alzheimer’s Drug Kisunla Gets MHRA Yes, But NICE Says No（邦訳：アルツハイマー治療薬ケサンラ承認で議論再び、薬価負担に悩む英国）」
URL:　 https://insights.citeline.com/pink-sheet/geography/europe/united-kingdom/deja-vu-in-england-lillys-alzheimers-drug-kisunla-gets-mhra-yes-but-nice-says-no-OX4YRPW4AFAYXAQVANZSSHURP4/
※全文の閲覧には購読（有料）が必要です。
世界の製薬ビジネスメディアScrip（スクリップ）とは？
https://www.citeline.com/ja-jp/products-services/commercialization/scrip


【3分で解説  世界のファーマ】第22回 AD治療、費用対効果に悩む英国 (Japanese-language podcast)

Audio roundup of selected biopharma industry content from Scrip over the business week ended 1 November 2024. In this episode: Lilly plans DTC tirzepatide ads; Pfizer’s Bourla defends strategy; expert views from BioFuture; China retains attractions for some; and AbbVie’s Aliada acquisition.

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things




Scrip's Five Must-Know Things - 5 November 2024

In this week’s Digital Health Roundup, Medtech Insight’s Marion Webb talks about her interview with GE HealthCare’s chief AI officer Parminder Bhatia at HTLH on his vision for AI in health care. Natasha Barrow discusses her interview with Owkin on the EU AI Act and highlights Click Therapeutics’ latest clinical results.

Digital Health Roundup: GE HealthCare On AI At HLTH; EU AI Act, Click Therapeutics

Pink Sheet reporter and editors discuss potential changes that the incoming Trump Administration could make on the FDA, as well as worries about political interference in decision-making, and policy and staffing changes.

More On These Topics From The Pink Sheet

US FDA’s Drug Approval Norms Could Be Upended In Second Trump Term: https://insights.citeline.com/pink-sheet/legislation/elections/us-fdas-drug-approval-norms-could-be-upended-in-second-trump-term-ICH6FUN4OBHRJPN4QFJ4OPLHNU/

Warp Speed For All And A Boost For Small Biotechs In Trump’s Second Term, Ex-Official Says: https://insights.citeline.com/pink-sheet/legislation/elections/warp-speed-for-all-and-a-boost-for-small-biotechs-in-trumps-second-term-ex-official-says-DA3BUPKEWVGVNDEPG6JMVLV7UI/

With Trump’s Return, Pharma Trades Disagreeable Knowns For Uncertainty: https://insights.citeline.com/pink-sheet/legislation/elections/with-trumps-return-pharma-trades-disagreeable-knowns-for-uncertainty-N7ZMT6QOEZEUDEXOROKXAZBP6E/

FTC Under Trump Likely to Maintain PBM Focus But M&A Oversight May Moderate: https://insights.citeline.com/pink-sheet/legislation/elections/ftc-under-trump-likely-to-maintain-pbm-focus-but-ma-oversight-may-moderate-H3XQ4S3YJBDSBK2NIDZFM4ZQ34/

Drug Fix: How Will Trump’s Second Term Impact The US FDA?

Audio roundup of selected biopharma industry content from Scrip over the business week ended 8 November 2024. In this episode: what Trump might mean for pharma; Novo’s semaglutide hits mark in NASH; AstraZeneca leads the way in clinical trials; Viking’s weight loss data excite; and how to speed up MLR reviews. 
https://insights.citeline.com/scrip/quick-listen-scrips-five-must-know-things-D4FI3E5BCNF2HNIP6TPK5KQ2A4/

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Scrip's Five Must-Know Things - 11 November 2024

In the latest episode of the In Vivo podcast, Noam Solomon, co-founder and CEO of Israeli-American biotech Immunai explains how his company is mapping the immune system and using AI to predict individual immune responses to drugs. Noam also discusses the company's own acquisitions, partnerships, the differences between innovation and invention, artificial biomedical intelligence (ABI) and barriers to personalized medicine. 

Using AI To Predict Our Immune Responses

Contract development and manufacturing organizations (CDMOs) are reshaping pharmaceutical production, playing a pivotal role in supply chain stability and driving innovation. 

In today’s fast-evolving environment, CDMOs help life sciences companies enhance speed, flexibility, and efficiency, which ultimately advances access to life-saving therapies. Norstella provides tailored insights, tools, and intelligence solutions to support this progress, empowering companies to make informed decisions and optimize their manufacturing partnerships.

This year at CPHI Milan, our team observed key industry trends, including innovations to strengthen supply chains and enhance sustainable practices. At Citeline’s (a Norstella company) 11th Annual Global Generics & Biosimilars Awards, we also celebrated excellence in the generics sector. 

Following the conference, Andrea Charles, VP of custom content at Norstella, and Andrew Warmington, Citeline’s manufacturing editor, joined Izabela Chmielewska, managing editor of custom content, to discuss major takeaways – from the BIOSECURE Act’s influence on global operations to advancements in biomanufacturing. Together, they explored how Norstella and Citeline drive solutions to streamline the journey from pipeline to patient.

Conference Catch-Up: Navigating the Evolving CDMO Landscape

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.